ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,180.74
      0.00%
      US Tech 100
      17,585.20
      -0.14%
      Dow Jones
      38,852.27
      0.00%
      Brent Oil
      82.845
      -0.75%
      Bitcoin
      63,622.13
      0.72%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Allogene Therapeutics Inc (ALLO)

      7. Allogene Therapeutics Inc (ALLO) News

      ALLO

      Allogene Therapeutics (ALLO)

      Allogene Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:ALLO
      DateTimeSourceHeadlineSymbolCompany
      05/06/20248:30AMGlobeNewswire Inc.Allogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
      04/26/20248:30AMGlobeNewswire Inc.Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell CarcinomaNASDAQ:ALLOAllogene Therapeutics Inc
      04/09/20248:30AMGlobeNewswire Inc.Allogene Therapeutics Announces Q2 Investor Conference ParticipationNASDAQ:ALLOAllogene Therapeutics Inc
      03/14/20244:05PMGlobeNewswire Inc.Allogene Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
      03/12/20248:30AMGlobeNewswire Inc.Allogene Therapeutics and Arbor Biotechnologies Announce Global Gene Editing Licensing Agreement to Support Advancement of Next-Generation Allogeneic CAR T Platform in Autoimmune DiseaseNASDAQ:ALLOAllogene Therapeutics Inc
      03/05/20248:30AMGlobeNewswire Inc.Allogene Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
      02/28/20248:30AMGlobeNewswire Inc.Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
      02/16/20248:30AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
      02/16/20248:30AMGlobeNewswire Inc.Allogene Therapeutics to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Related to the December 2020 Formation of the Allogene Overland Biopharm Joint Venture in AsiaNASDAQ:ALLOAllogene Therapeutics Inc
      01/31/20245:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
      01/24/20245:25PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
      01/22/20244:11PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
      01/16/20244:05PMGlobeNewswire Inc.Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesNASDAQ:ALLOAllogene Therapeutics Inc
      01/05/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
      01/04/20244:15PMGlobeNewswire Inc.Allogene Therapeutics and Foresight Diagnostics Announce Partnership to Develop MRD-based In-Vitro Diagnostic for Use in ALPHA3, the First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaNASDAQ:ALLOAllogene Therapeutics Inc
      01/04/20244:05PMGlobeNewswire Inc.Allogene Therapeutics Announces 2024 Platform Vision to Redefine the Future of CAR T Led by ALPHA3, the Industry's First Pivotal Trial for Frontline Consolidation in Large B-Cell LymphomaNASDAQ:ALLOAllogene Therapeutics Inc
      01/03/20244:05PMGlobeNewswire Inc.Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
      12/20/20234:26PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
      12/19/20233:46PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
      12/18/20234:17PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ALLOAllogene Therapeutics Inc
      12/09/202312:00PMGlobeNewswire Inc.Allogene Therapeutics Presents Comprehensive Safety Data of Proprietary Lymphodepletion Agent ALLO-647 at the 65th Annual Meeting of the American Society of HematologyNASDAQ:ALLOAllogene Therapeutics Inc
      12/01/20238:30AMGlobeNewswire Inc.Allogene Therapeutics Announces Participation in December Investor ConferenceNASDAQ:ALLOAllogene Therapeutics Inc
      11/03/202312:00PMGlobeNewswire Inc.Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
      11/03/202312:00PMGlobeNewswire Inc.Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual MeetingNASDAQ:ALLOAllogene Therapeutics Inc
      11/02/20234:41PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ALLOAllogene Therapeutics Inc
      11/02/20234:06PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ALLOAllogene Therapeutics Inc
      11/02/20234:03PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:ALLOAllogene Therapeutics Inc
      11/02/20234:02PMGlobeNewswire Inc.Allogene Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdateNASDAQ:ALLOAllogene Therapeutics Inc
      11/02/20239:00AMGlobeNewswire Inc.Allogene Therapeutics Announces Poster Presentations at the 65th Annual Meeting of the American Society of HematologyNASDAQ:ALLOAllogene Therapeutics Inc
      10/30/20238:30AMGlobeNewswire Inc.Allogene Therapeutics Announces Participation in November Investor ConferencesNASDAQ:ALLOAllogene Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:ALLO